Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Revenue Recognition (Tables)

v3.19.3.a.u2
Revenue Recognition (Tables)
12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Asset and Liability The following table summarizes the values of contract assets, capitalized commissions and contract liabilities as of December 31, 2019 and December 31, 2018 (in thousands):
December 31, 2019 December 31, 2018
Current pharma contract assets (1)
$ 1,000    $ 86   
Long-term pharma contract assets (2)
153    268   
Total pharma contract assets $ 1,153    $ 354   
Current pharma capitalized commissions (1)
$ 133    $ 271   
Long-term pharma capitalized commissions (2)
798    650   
Total pharma capitalized commissions $ 931    $ 921   
Current pharma contract liabilities $ 1,610    $ 927   
Long-term pharma contract liabilities (3)
1,171    1,652   
Total pharma contract liabilities $ 2,781    $ 2,579   

(1) Current pharma contract assets and current pharma capitalized commissions are classified as “Other current assets” on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and long-term pharma capitalized commissions are classified as “Other assets” on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as “Other long-term liabilities” on the Consolidated Balance Sheets.
Disaggregation of Revenue The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
December 31, 2019 December 31, 2018 December 31, 2017
Clinical Services:
    Client direct billing $ 212,703    $ 164,888    $ 147,726   
    Commercial Insurance 83,107    40,360    35,473   
    Medicare and Medicaid 64,745    35,566    29,493   
    Self-Pay 606    1,059    405   
Total Clinical Services 361,161    241,873    213,097   
Pharma Services: 47,669    34,868    27,154   
Total Revenue $ 408,830    $ 276,741    $ 240,251